Aesthetic Dermatology

Evonik supplies high-purity bioresorbable polymer powders — including Poly-L-lactic acid (PLLA), polycaprolactone (PCL), and polydioxanone (PDO) — used by medical device manufacturers to formulate next-generation aesthetic injectables. Built on more than 30 years of experience in medical-grade biomaterials, our RESOMER® Powder Platform helps formulators develop next-generation aesthetic injectables aligned with growing interest in regenerative treatment approaches.

RESOMER® bioresorbable polymers have over 30 years of documented use in implantable and injectable medical applications, providing manufacturers with materials backed by an extensive history of clinical use and regulatory familiarity.  For manufacturers developing new formulations, this track record offers a proven starting point — both in terms of material performance, processing support and regulatory maturity.

Consumer expectations in medical aesthetics are shifting faster than in almost any other segment of the industry. Since the first hyaluronic acid-based dermal filler reached the market in 2003, demand has steadily moved beyond simple volume restoration toward products designed to support natural regenerative processes  and deliver a more natural-looking result over time.

To meet this shift, dermal filler manufacturers are increasingly formulating with bioresorbable polymers such as PLLA, PCL, and PDO — materials that don't just fill space, but actively interact with tissue as they gradually resorb.

At the core of our offering is the RESOMER® Powder Platform: a portfolio of ultra-fine bioresorbable powders and microgranules purpose-built for injectable aesthetic formulations. The platform includes standard RESOMER® powder grades as well as RESOMER® Powder Select, which offers customization options for specific formulation requirements. 

Powders are produced using Evonik's proprietary solvent-free micronization technology, which enables high-purity, ultra-fine bioresorbable powders without solvent residues — a key requirement for consistent injectability and suspension stability.

Platform advantages at a glance:

• ISO 13485 and GMP manufacturing
• Cleanroom processing (ISO Class 8)
• Configurable particle size and characteristics to support formulation goals
• Scalable production, from small laboratory batches to full commercial volumes

This combination of purity, consistency, and customization gives manufacturers a way to differentiate their formulations while reducing development risk and accelerating time-to-market.

Different bioresorbable polymers offer distinct degradation profiles, mechanical characteristics, and formulation opportunities. The optimal material selection depends on the intended product design, performance objectives, and development requirements.

Within the Evonik portfolio, suitable materials for medical aesthetic applications are available across the RESOMER® L-series (PLLA), R-series (PDLLA), X-series (PDO), C-series (PCL), and selected copolymer platforms. Our technical team works closely with manufacturers to evaluate polymer options and identify materials aligned with their formulation and product-development goals.

Material characteristics, including molecular weight and particle properties, can influence formulation behavior and final product attributes. Through the RESOMER® Powder Platform and RESOMER® Powder Select, Evonik offers customization capabilities to support application-specific development needs.

In addition to RESOMER®, Evonik offers VECOLLAN®, a recombinant, non-animal-derived collagen-like biomaterial platform. Produced through advanced biotechnology, VECOLLAN® combines purity, scalability, and design flexibility, opening up new possibilities for biomimetic and regenerative aesthetic products. VECOLLAN® can be processed into hydrogel formulations, supporting development of next-generation biomimetic aesthetic products.